taltirelin tetrahydrate
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Feb 20, 2019 (NCT04107740)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
Thyrotropin-releasing hormone receptor agonist
- Thyrotropin-releasing hormone receptorSupplementation
TRHR supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)C[C@@H](C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O- Mol. weight
- 405.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107016 ↗
Also known as
- ceredist
- ta 0910
- ta-0910
- taltirelin
- taltirelin
- taltirelin hydrate
- taltirelin hydrate
- taltirelin hydrate
- taltirelin hydrate
- taltirelin tetrahydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04107740 | Phase 4 | Feb 20, 2019 | Chem Tech Research Incorporation, Korea University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chem Tech Research Incorporation | For profit | 1 | 1 | 1 | 2019 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1